Journal: PLoS ONE

Article Title: Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas

doi: 10.1371/journal.pone.0238238

Figure Lengend Snippet: MGMT-expressing variants (i.e., LN229M, U251M, and GL261M) of three well-established GB cell lines were checked along with their parental cells as well as the T98G (an endogenous high MGMT expressor) and LN229TR2 (an MMR-deficient variant of LN229) GB cells for MGMT expression by Western blotting (panel A). Colony survival data are also shown for all three isogenic GB cell lines (panel B). The O6BG MGMT inhibitor (40 μΜ) was used to demonstrate that the artificially expressed MGMT proteins in LN229M, U251M, and GL261M cells were functional and respond to specific inhibition (i.e., the MGMT-positive cells are sensitized to both alkylating agents after the addition of the O6BG inhibitor).

Article Snippet: A rabbit polyclonal antibody that crossreacts with both human MGMT and mouse Mgmt proteins was purchased from Boster Biological Technology (Pleasanton, CA) and used in this Western-blot analysis.

Techniques: Expressing, Variant Assay, Western Blot, Functional Assay, Inhibition

Journal: PLoS ONE

Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

doi: 10.1371/journal.pone.0253687

Figure Lengend Snippet: Median age was 65.5 years for cohort I and 69.5 years for cohort II at the time of routine ctDNA EGFR analyses.

Article Snippet: In our setup, the SensiScreen ® EGFR Liquid assay platform (PentaBase) outperformed the Therascreen ® platform (Qiagen) and showed 100% agreement at the sequence level to the IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific).

Techniques:

Journal: PLoS ONE

Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

doi: 10.1371/journal.pone.0253687

Figure Lengend Snippet: PCR curves obtained when challenging assays with cell lines or plasmids containing the indicated EGFR mutations. Plasmids were diluted 1:1 in WT gDNA to ensure a total template amount of 1600 copies. Reference assay PCR curves are represented by heavy coloured lines and mutation specific assay PCR curves by light coloured lines as indicated in figure legends. Abbreviations: Ct, Cycle threshold; EGFR, Epidermal growth factor receptor.

Article Snippet: In our setup, the SensiScreen ® EGFR Liquid assay platform (PentaBase) outperformed the Therascreen ® platform (Qiagen) and showed 100% agreement at the sequence level to the IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific).

Techniques: Mutagenesis

Journal: PLoS ONE

Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

doi: 10.1371/journal.pone.0253687

Figure Lengend Snippet: A. Histograms showing the frequency and distribution of mutant copies detected in 102 replicates for assays. B. Boxplot showing the collectively recovered number of copies by the three assays and thereby the overall detected copy number by assays. Abbreviations: EGFR, Epidermal growth factor receptor.

Article Snippet: In our setup, the SensiScreen ® EGFR Liquid assay platform (PentaBase) outperformed the Therascreen ® platform (Qiagen) and showed 100% agreement at the sequence level to the IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific).

Techniques: Mutagenesis

Journal: PLoS ONE

Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

doi: 10.1371/journal.pone.0253687

Figure Lengend Snippet: Repeatability and accuracy evaluation of SensiScreen ® EGFR Liquid assays: Number of copies mutated for Exon 19 deletion, T790M or L858R.

Article Snippet: In our setup, the SensiScreen ® EGFR Liquid assay platform (PentaBase) outperformed the Therascreen ® platform (Qiagen) and showed 100% agreement at the sequence level to the IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific).

Techniques:

Journal: PLoS ONE

Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

doi: 10.1371/journal.pone.0253687

Figure Lengend Snippet: Graphs describing the LoB evaluation based on the characterization of repeated testing of cfDNA pooled from 58 healthy donors A. Curves representing the T790M LoB results. B. Curves representing the L858R LoB results. C. Curves representing the EGFR exon 19 deletion LoB results.

Article Snippet: In our setup, the SensiScreen ® EGFR Liquid assay platform (PentaBase) outperformed the Therascreen ® platform (Qiagen) and showed 100% agreement at the sequence level to the IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific).

Techniques:

Journal: PLoS ONE

Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

doi: 10.1371/journal.pone.0253687

Figure Lengend Snippet: Overview of the EGFR phenotypes detected by the Therascreen ® (QIAGEN) versus SensiScreen ® EGFR Liquid assay (Pentabase) and IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific) using cohort I and agreement or disagreement between platforms (N = 34).

Article Snippet: In our setup, the SensiScreen ® EGFR Liquid assay platform (PentaBase) outperformed the Therascreen ® platform (Qiagen) and showed 100% agreement at the sequence level to the IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific).

Techniques:

Journal: PLoS ONE

Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

doi: 10.1371/journal.pone.0253687

Figure Lengend Snippet: Overview of the EGFR phenotypes detected by the SensiScreen ® EGFR Liquid assay (PentaBase ApS) versus the ctEGFR Mutation Detection Kit (EntroGen) using cohort II and agreement or disagreement between platforms (N = 34).

Article Snippet: In our setup, the SensiScreen ® EGFR Liquid assay platform (PentaBase) outperformed the Therascreen ® platform (Qiagen) and showed 100% agreement at the sequence level to the IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific).

Techniques: Mutagenesis

Journal: Neuro-Oncology Practice

Article Title: Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival

doi: 10.1093/nop/npy028

Figure Lengend Snippet: Cox Regression Analysis of Overall Survival and Progression-Free Survival of 102 Primary Glioblastoma MGMT Unmethylated Patients With Substratification by MGMT Values

Article Snippet: Our patient cohort was derived retrospectively and consisted of newly diagnosed GBM patients seen at UCLA and KPLA between 2011 and 2016 with accessible LabCorp quantitative MGMT methylation values.

Techniques: Biomarker Discovery

Journal: Neuro-Oncology Practice

Article Title: Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival

doi: 10.1093/nop/npy028

Figure Lengend Snippet: Kaplan-Meier analysis is used to A, compare the MGMT (1-1.99) vs MGMT (<1) and MGMT (≥2) patients. The MGMT (1-1.99) group’s median OS (25.4 months) falls in between the MGMT (≥2) (38.8 months) and MGMT (<1) (17.3 months) median OS values (Log-rank P = .001). B, PFS showed the same trend, namely the MGMT (1-1.99) group generated a higher median OS of 11.8 months compared to the MGMT (<1) group but lower than the MGMT (≥ 2) group, yielding 11.8 months vs 7.92 months and 18.0 months (Log-rank P < .0001), respectively. MGMT indicates O-6-methylguanine-DNA methyltransferase; mo, months; OS, overall survival; PFS, progression-free survival.

Article Snippet: Our patient cohort was derived retrospectively and consisted of newly diagnosed GBM patients seen at UCLA and KPLA between 2011 and 2016 with accessible LabCorp quantitative MGMT methylation values.

Techniques: Generated

Journal: Neuro-Oncology Practice

Article Title: Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival

doi: 10.1093/nop/npy028

Figure Lengend Snippet: Cox Regression Analysis of Overall Survival and Progression-Free Survival of 165 Primary Glioblastoma Patients With Substratification by MGMT Values

Article Snippet: Our patient cohort was derived retrospectively and consisted of newly diagnosed GBM patients seen at UCLA and KPLA between 2011 and 2016 with accessible LabCorp quantitative MGMT methylation values.

Techniques: Biomarker Discovery

Journal: Frontiers in Genetics

Article Title: Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial

doi: 10.3389/fgene.2022.934519

Figure Lengend Snippet: Patients from the Nordic trial included in the study. Patients with good prognostic factors were selected from each treatment arm (temozolomide -TMZ, radiotherapy 34Gy-RT 34Gy, and radiotherapy 60Gy- RT60Gy). Half of the tumors had methylated MGMT promoter (m-MGMT), and half had unmethylated MGMT promoter (u-MGMT). These patients were further divided into long-term survivors (LTS) and short-term survivors (STS). N, number of patients.

Article Snippet: The MGMT methylation status was analyzed with the MDxHealth method, Liège, Belgium, as mentioned in ).

Techniques: Methylation

Journal: Frontiers in Genetics

Article Title: Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial

doi: 10.3389/fgene.2022.934519

Figure Lengend Snippet: Patient characteristics.

Article Snippet: The MGMT methylation status was analyzed with the MDxHealth method, Liège, Belgium, as mentioned in ).

Techniques: Biomarker Discovery, Methylation

Journal: Frontiers in Genetics

Article Title: Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial

doi: 10.3389/fgene.2022.934519

Figure Lengend Snippet: Pie charts representing the structural genomic distribution of DMCs discovered in samples with long ( n = 3) and short ( n = 3) survival within the different treatment arms and with specified MGMT promoter methylation status. TSS200, 200 bases upstream transcription start site; TSS1500, 1,500 bases upstream transcription start site; UTR, untranslated region; IGR, intergenic region; 60Gy34Gy, combined RT.

Article Snippet: The MGMT methylation status was analyzed with the MDxHealth method, Liège, Belgium, as mentioned in ).

Techniques: Methylation

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Summary of Cohort Characteristics and Treatments

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques: Methylation, Biomarker Discovery

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Overall survival (OS) outcomes of patients stratified by MGMT promoter methylation status. (A) OS of the entire patient cohort. (B) OS of patients diagnosed with glioblastoma multiforme (GBM). (C) OS of patients diagnosed with anaplastic astrocytoma (AA) and low-grade astrocytoma (LA). (D) OS of patients diagnosed with anaplastic oligodendroglioma (AO) and low-grade oligodendroglioma (LO). (E) OS of patients diagnosed with AA. (F) OS of patients diagnosed with LA. (G) OS of patients diagnosed with AO. (H) OS of patients diagnosed with LO.

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques: Methylation

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Multivariate Analysis of OS in Various Pathological Subgroups

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques:

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Progression-free survival (PFS) outcomes of patients stratified by MGMT promoter methylation status. (A) PFS of the entire patient cohort. (B) PFS of patients diagnosed with glioblastoma multiforme (GBM). (C) PFS of patients diagnosed with anaplastic astrocytoma (AA) and low-grade astrocytoma (LA). (D) PFS of patients diagnosed with anaplastic oligodendroglioma (AO) and low-grade oligodendroglioma (LO). (E) PFS of patients diagnosed with AA. (F) PFS of patients diagnosed with LA. (G) PFS of patients diagnosed with AO. (H) PFS of patients diagnosed with LO.

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques: Methylation

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Multivariate Analysis of PFS in Various Pathological Subgroups

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques:

Journal: Neuro-Oncology Practice

Article Title: Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival

doi: 10.1093/nop/npy028

Figure Lengend Snippet: Cox Regression Analysis of Overall Survival and Progression-Free Survival of 102 Primary Glioblastoma MGMT Unmethylated Patients With Substratification by MGMT Values

Article Snippet: In this retrospective study, we sought to examine whether the magnitude of MGMT methylation as determined by LabCorp 4 testing (versus a single stratification based on a cutoff of 2) better correlates with outcome in our GBM patients from 2011 to 2016.

Techniques: Biomarker Discovery

Journal: Neuro-Oncology Practice

Article Title: Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival

doi: 10.1093/nop/npy028

Figure Lengend Snippet: Kaplan-Meier analysis is used to A, compare the MGMT (1-1.99) vs MGMT (<1) and MGMT (≥2) patients. The MGMT (1-1.99) group’s median OS (25.4 months) falls in between the MGMT (≥2) (38.8 months) and MGMT (<1) (17.3 months) median OS values (Log-rank P = .001). B, PFS showed the same trend, namely the MGMT (1-1.99) group generated a higher median OS of 11.8 months compared to the MGMT (<1) group but lower than the MGMT (≥ 2) group, yielding 11.8 months vs 7.92 months and 18.0 months (Log-rank P < .0001), respectively. MGMT indicates O-6-methylguanine-DNA methyltransferase; mo, months; OS, overall survival; PFS, progression-free survival.

Article Snippet: In this retrospective study, we sought to examine whether the magnitude of MGMT methylation as determined by LabCorp 4 testing (versus a single stratification based on a cutoff of 2) better correlates with outcome in our GBM patients from 2011 to 2016.

Techniques: Generated

Journal: Neuro-Oncology Practice

Article Title: Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival

doi: 10.1093/nop/npy028

Figure Lengend Snippet: Cox Regression Analysis of Overall Survival and Progression-Free Survival of 165 Primary Glioblastoma Patients With Substratification by MGMT Values

Article Snippet: In this retrospective study, we sought to examine whether the magnitude of MGMT methylation as determined by LabCorp 4 testing (versus a single stratification based on a cutoff of 2) better correlates with outcome in our GBM patients from 2011 to 2016.

Techniques: Biomarker Discovery

Journal: Cancer Imaging

Article Title: Assessment of MGMT promoter methylation status in glioblastoma using deep learning features from multi-sequence MRI of intratumoral and peritumoral regions

doi: 10.1186/s40644-024-00817-1

Figure Lengend Snippet: Segmentation illustration of tumor T1WI and CE-T1WI sequence imaging. Patient a is a 66-year-old male with unmethylated MGMT status, and patient b is a 68-year-old female with methylated MGMT status. The red region represents the NCR, the yellow region represents the ET, and the green region represents the PED

Article Snippet: The inclusion criteria included: (1) comprehensive imaging, pathological, and clinical data; (2) pathological confirmation of glioblastoma (WHO CNS 2021) with a definitive diagnosis of MGMT promoter methylation status (in house method developed by UCSF clinical labs, https://genomics.ucsf.edu/content/mgmt-promoter-methylation-assay ); (3) surgical intervention within one week following MRI examination; and (4) absence of any prior surgical, radiotherapy, or chemotherapy treatments before the MRI examination.

Techniques: Sequencing, Imaging, Methylation

Journal: Cancer Imaging

Article Title: Assessment of MGMT promoter methylation status in glioblastoma using deep learning features from multi-sequence MRI of intratumoral and peritumoral regions

doi: 10.1186/s40644-024-00817-1

Figure Lengend Snippet: Prediction results of MGMT promoter methylation status using different models

Article Snippet: The inclusion criteria included: (1) comprehensive imaging, pathological, and clinical data; (2) pathological confirmation of glioblastoma (WHO CNS 2021) with a definitive diagnosis of MGMT promoter methylation status (in house method developed by UCSF clinical labs, https://genomics.ucsf.edu/content/mgmt-promoter-methylation-assay ); (3) surgical intervention within one week following MRI examination; and (4) absence of any prior surgical, radiotherapy, or chemotherapy treatments before the MRI examination.

Techniques: Methylation